Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PharmaEngineROCO:4162 -4.07%83 PS Ratio is 10.12 as of Jul. 19, 2026, which is 50% below its 10-year median of 20.08. GuruFocus rates ROCO:4162 with a GF Score™ of 83/100 and a GF Value™ of NT$115.66 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 931 Biotechnology companies, PharmaEngine ranks worse than 52.2% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, PharmaEngine's share price is NT$63.70.
PharmaEngine's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$6.30. Hence, PharmaEngine's PS Ratio for today is 10.12.
The historical rank and industry rank for PharmaEngine's PS Ratio or its related term are showing as below:
ROCO:4162'
s PS Ratio Range Over the Past 10 Years
Min: 3.81 Med: 20.08 Max: 78.27
Current: 10.12
During the past 13 years, PharmaEngine's highest PS Ratio was 78.27. The lowest was 3.81. And the median was 20.08.
ROCO:4162's PS Ratio is ranked worse than 52.2% of 931
companies
in the Biotechnology industry
Industry Median: 9.32
vs ROCO:4162: 10.12
PharmaEngine Inc revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of PharmaEngine was -63.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 11.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 10.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 8.00% per year.
During the past 13 years, PharmaEngine's highest 3-Year average Revenue per Share Growth Rate was 203.10% per year. The lowest was -34.60% per year. And the median was 19.95% per year.
Back to Basics: PS Ratio
PharmaEngine (ROCO:4162) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
PharmaEngine PS Ratio Related Terms
PharmaEngine PS Ratio Historical Data
* Premium members only.
The historical data trend for PharmaEngine's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4162 vs VRTX, REGN, ALNY: PS Ratio Comparison
For the Biotechnology subindustry, PharmaEngine's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaEngine PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PharmaEngine's PS Ratio distribution charts can be found below:
* The bar in red indicates where PharmaEngine's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
PharmaEngine's PS Ratio for today is calculated as
PharmaEngine's Share Price of today is NT$63.70. PharmaEngine's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$6.30.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PharmaEngine (ROCO:4162) has a PS Ratio of 10.12 as of Jul. 19, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on PharmaEngine and its competitors. This is 50% below median its historical median of 20.08. Over the past decade, PharmaEngine's PS Ratio has ranged from 3.81 to 78.27. According to the industry distribution chart, PharmaEngine ranks #486 out of 931 companies in the Biotechnology industry, placing it in the top 52.2%.
Is PharmaEngine's PS Ratio too high?
PharmaEngine's current PS Ratio of 10.12 is 50% below median its 10-year median of 20.08. Over the past 10 years, this metric has ranged from a low of 3.81 to a high of 78.27. The Biotechnology industry median PS Ratio is 9.32. PharmaEngine's value of 10.12 is 8.6% above this industry median. Based on the distribution chart, PharmaEngine ranks #486 out of 931 companies in the Biotechnology industry, which is below the industry midpoint. Overall, PharmaEngine has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PharmaEngine's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PharmaEngine ranks #486 out of 931 companies for PS Ratio. This places PharmaEngine in the lower half of its industry. The industry median PS Ratio is 9.32. PharmaEngine's value of 10.12 is 8.6% above this benchmark. Historically, PharmaEngine's own PS Ratio has ranged from 3.81 to 78.27 over the past decade. While the company's 10-year median is 20.08 vs. the industry median of 9.32, PharmaEngine has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.32, based on 931 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmaEngine's current PS Ratio of 10.12 is 8.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on PharmaEngine and its competitors. For the Biotechnology industry, the median PS Ratio is 9.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaEngine's current PS Ratio is 10.12, which is 50% below median its own 10-year median of 20.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaEngine stock overvalued right now?
Based on GuruFocus' analysis, PharmaEngine (ROCO:4162) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$115.66, compared to a current price of NT$63.70 — trading 44.9% below its estimated fair value. The current PS Ratio is 10.12, which is 50% below median its 10-year median of 20.08 and 8.6% above the Biotechnology industry median of 9.32. PharmaEngine's overall GF Score™ is 83/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For PharmaEngine (ROCO:4162), the current PS Ratio is 10.12 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PharmaEngine (ROCO:4162) Overvalued in 2026?
Based on GuruFocus' analysis, PharmaEngine stock appears to be undervalued.
The current stock price of NT$63.70 is trading 44.9% below its estimated GF Value™ of NT$115.66.
GuruFocus considers PharmaEngine to be Significantly Undervalued.
Key valuation signals for ROCO:4162:
PS Ratio: 10.12 (50% below median its 10-year median of 20.08)
GF Value™: NT$115.66 vs. price of NT$63.70 (44.9% below fair value)
Industry Position: 8.6% above the Biotechnology median (#486 of 931)
No single metric tells the full story. See the ROCO:4162 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PharmaEngine Inc is a biopharmaceutical company engaged in the development of new drugs and therapeutic drugs for cancer. It is a specialty pharma company that adopts the no research, development-only model and the networked pharma model for new drug development. Its key products and pipeline projects include ONIVYDE, a treatment for metastatic pancreatic cancer approved in multiple markets, as well as oncology candidates such as PEP07 and PEP08. It generates revenue from the sales of goods.
83GF Score
Get the complete analysis for ROCO:4162
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4162 has been successfully added to your 
